Dr. Michael F. Driscoll, M.D.
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Louisiana State University School of Medicine in Shreveport (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 499
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Medical school: Louisiana State University School of Medicine in Shreveport
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
KY license 43073
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Norton Hospitals, Inc Louisville, KY
- Uofl Health - Jewish Hospital and Mary & Elizabeth Hospital Louisville, KY
- Baptist Health Hardin Elizabethtown, KY
Medical groups
- Norton Hospitals, Inc (137 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 499
- Services billed
- 2,481
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 666 | 182 |
| Established patient office or other outpatient visit, 30-39 minutes | 515 | 320 |
| New patient office or other outpatient visit, 60-74 minutes | 69 | 69 |
| New patient office or other outpatient visit, 45-59 minutes | 26 | 26 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Eliquis (apixaban) Other prescribers in Louisville, KY | 138 |
| Oxycodone-Acetaminophen (oxycodone hcl/acetaminophen) Other prescribers in Louisville, KY | 122 |
| Ondansetron Hcl Other prescribers in Louisville, KY | 105 |
| Oxycodone Hcl Other prescribers in Louisville, KY | 104 |
| Anastrozole Other prescribers in Louisville, KY | 94 |
| Morphine Sulfate Er (morphine sulfate) Other prescribers in Louisville, KY | 70 |
| Promethazine Hcl Other prescribers in Louisville, KY | 63 |
| Warfarin Sodium Other prescribers in Louisville, KY | 55 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Louisville, KY | 48 |
| Ibandronate Sodium Other prescribers in Louisville, KY | 42 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 6 payments worth $499 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $210 |
|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $113 |
| Amgen Inc. | $102 |
| Merck Sharp & Dohme LLC | $74.34 |
| Food and Beverage | $499 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 6 companies. The companies reported $1,378,170 in research payments for these studies, mostly to the institutions running them.
- An openlabel randomized phase 3 study of tucatinib in combination with trastuzumab and MFOLFOX6 versus MFOLFOX6 given with or without either cetuximab or bevacizumab as firstline treatment for subjects with HER2 metas…
Pfizer Inc. - A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab MK-3475 Lenvatinib E7080,MK-7902 Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastati…
Merck Sharp & Dohme LLC - A randomized,phase third study of rilvegostomig in combination with fluoropyrimidine and trastuzumab deruxtecan versus trastuzumab,chemotherapy,and pembrolizumab for the first line treatment of positive gastric cancer
AstraZeneca Pharmaceuticals LP - Atezolizumab and bevacizumab tiragolumab in 1L unresectable hcc pts
Genentech, Inc. - A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer.
Jazz Pharmaceuticals Inc. - A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
AbbVie Inc. · Active, not recruiting · NCT06109272 - A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician s Choice in 3L Advanced,Metastatic Gastroesophageal Adenocarcinoma Gastric Adenocarcinom…
Merck Sharp & Dohme LLC - A randomized doubleblind phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for metastatic HER2 breast cancer HER2CLIMB05
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.